Roche wins Japan approval for personalised cancer drug Rozlytrek

Reuters

18 June 2019 - Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

Japan is the first country to give its blessing to Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types including breast, colorectal, neuroendocrine, lung and pancreatic cancers.

Rozlytrek aims to treat people with a rare genetic anomaly, called NTRK fusions, that drive growth in a range of tumours found throughout the body. This approach, where prospective patients must be identified via a biomarker test, is a departure from an era when doctors treated patients based on where the tumour occurred in the body.

Read Reuters article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Japan